Large-Scale High Titer Lentiviral Production Using Lonza's Suspension Transient Transfection Platform

Lentivirus vector (LVV) is a major player in cell and gene therapies. It efficiently transduces both dividing and non-dividing cells and is able to incorporate large transgenes, making it a versatile viral vector for a number of applications where gene delivery is required. Given the growing demand for the LVV-based therapies, Lonza developed an Xcite® LVV suspension transient transfection platform using a proprietary HEK293T cell line. The platform utilizes a transient transfection with a plasmid expressing the gene of interest (GOI) and three packaging plasmids and can be scaled up to 250L production and transferred to GMP manufacturing.